Atlas funds trim Kymera (NASDAQ: KYMR) stake under 10b5-1 plan

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

4/A

Rhea-AI Filing Summary

Kymera Therapeutics director-related entities reported an amended open-market sale of Kymera common stock. Entities associated with Bruce Booth, including Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., sold a total of 76,650 shares of Kymera Therapeutics, Inc. on June 29, 2026.

The trades were executed as open-market sales at weighted average prices within ranges from about $105.02 to $111.63 per share under a Rule 10b5-1 trading plan adopted on December 11, 2025. The filing is an amendment that corrects previously misreported numbers of shares disposed and owned following the transactions. Booth reports these holdings indirectly through the Atlas funds and disclaims Section 16 beneficial ownership except for any pecuniary interest.

Insights

Pre-planned fund-level sales totaling 76,650 Kymera shares, corrected via amended Form 4, look routine.

Entities affiliated with Bruce Booth sold 76,650 shares of Kymera Therapeutics common stock on June 29, 2026, across 14 open-market transactions. Prices ranged roughly from $105.02 to $111.63 per share, indicating execution over a trading range rather than a single block sale.

The sales were made under a pre-established Rule 10b5-1 trading plan adopted on December 11, 2025, which suggests these trades were scheduled in advance. The amendment corrects earlier misreported share amounts, improving data accuracy but not changing the economic substance. Booth reports the positions indirectly through Atlas funds and disclaims full Section 16 beneficial ownership, so activity reflects fund portfolio management rather than personal discretionary trading.

Insider Trade Summary 10b5-1

Net Seller: 76,650 shares ($8,281,905)

Net Sell 14 txns

Insider Booth Bruce

Role null

Sold 76,650 shs ($8.28M)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,549	$105.78	$587K
Sale	Common Stock	14,798	$106.63	$1.58M
Sale	Common Stock	19,419	$107.76	$2.09M
Sale	Common Stock	10,848	$108.28	$1.17M
Sale	Common Stock	7,968	$109.75	$874K
Sale	Common Stock	7,723	$110.67	$855K
Sale	Common Stock	934	$111.20	$104K
Sale	Common Stock	770	$105.78	$81K
Sale	Common Stock	2,133	$106.63	$227K
Sale	Common Stock	2,698	$107.76	$291K
Sale	Common Stock	1,498	$108.28	$162K
Sale	Common Stock	1,104	$109.75	$121K
Sale	Common Stock	1,078	$110.67	$119K
Sale	Common Stock	130	$111.20	$14K

Holdings After Transaction: Common Stock — 2,446,375 shares (Indirect, See footnote)

Footnotes (1)

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.015 to $106.0145 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (3) and (5) through (10). These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.0271 to $106.96 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.03 to $108.0293 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.0326 to $109.019 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.034 to $109.96 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.09 to $111.08 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.09 to $111.63 inclusive. The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any.

Key Figures

Total shares sold: 76,650 shares Lowest sale price range: $105.015–$106.0145 Highest sale price range: $111.09–$111.63 +3 more

6 metrics

Total shares sold 76,650 shares Open-market sales on June 29, 2026 across 14 transactions

Lowest sale price range $105.015–$106.0145 Weighted average price range noted in one transaction footnote

Highest sale price range $111.09–$111.63 Weighted average price range for higher-priced trades

Number of sale transactions 14 transactions Non-derivative open-market sales of common stock

Trading plan adoption date December 11, 2025 Rule 10b5-1 plan for Atlas funds covering these sales

Net buy/sell direction Net sale of 76,650 shares Transaction summary shows net-sell activity with no purchases

Key Terms

Rule 10b5-1 trading plan, weighted average price, Section 16 beneficial ownership, pecuniary interest, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.015 to $106.0145 inclusive."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Section 16 beneficial ownership regulatory

"The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."

pecuniary interest financial

"disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 05:39 PM Accepted by SEC EDGAR 07/02/2026 - 05:39 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Booth Bruce

(Last)

(First)

(Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, FLOOR 4

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
06/30/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/29/2026		S⁽¹⁾		5,549⁽²⁾	D	$105.78⁽³⁾	2,446,375⁽²⁾	I	See footnote⁽⁴⁾
Common Stock	06/29/2026		S⁽¹⁾		14,798⁽²⁾	D	$106.63⁽⁵⁾	2,431,577⁽²⁾	I	See footnote⁽⁴⁾
Common Stock	06/29/2026		S⁽¹⁾		19,419⁽²⁾	D	$107.76⁽⁶⁾	2,412,158⁽²⁾	I	See footnote⁽⁴⁾
Common Stock	06/29/2026		S⁽¹⁾		10,848⁽²⁾	D	$108.28⁽⁷⁾	2,401,310⁽²⁾	I	See footnote⁽⁴⁾
Common Stock	06/29/2026		S⁽¹⁾		7,968⁽²⁾	D	$109.75⁽⁸⁾	2,393,342⁽²⁾	I	See footnote⁽⁴⁾
Common Stock	06/29/2026		S⁽¹⁾		7,723⁽²⁾	D	$110.67⁽⁹⁾	2,385,619⁽²⁾	I	See footnote⁽⁴⁾
Common Stock	06/29/2026		S⁽¹⁾		934⁽²⁾	D	$111.2⁽¹⁰⁾	2,384,685⁽²⁾	I	See footnote⁽⁴⁾
Common Stock	06/29/2026		S⁽¹⁾		770⁽²⁾	D	$105.78⁽³⁾	471,497⁽²⁾	I	See footnote⁽¹¹⁾
Common Stock	06/29/2026		S⁽¹⁾		2,133⁽²⁾	D	$106.63⁽⁵⁾	469,364⁽²⁾	I	See footnote⁽¹¹⁾
Common Stock	06/29/2026		S⁽¹⁾		2,698⁽²⁾	D	$107.76⁽⁶⁾	466,666⁽²⁾	I	See footnote⁽¹¹⁾
Common Stock	06/29/2026		S⁽¹⁾		1,498⁽²⁾	D	$108.28⁽⁷⁾	465,168⁽²⁾	I	See footnote⁽¹¹⁾
Common Stock	06/29/2026		S⁽¹⁾		1,104⁽²⁾	D	$109.75⁽⁸⁾	464,064⁽²⁾	I	See footnote⁽¹¹⁾
Common Stock	06/29/2026		S⁽¹⁾		1,078⁽²⁾	D	$110.67⁽⁹⁾	462,986⁽²⁾	I	See footnote⁽¹¹⁾
Common Stock	06/29/2026		S⁽¹⁾		130⁽²⁾	D	$111.2⁽¹⁰⁾	462,856⁽²⁾	I	See footnote⁽¹¹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025.

2. The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.015 to $106.0145 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (3) and (5) through (10).

4. These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.0271 to $106.96 inclusive.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.03 to $108.0293 inclusive.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.0326 to $109.019 inclusive.

8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.034 to $109.96 inclusive.

9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.09 to $111.08 inclusive.

10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.09 to $111.63 inclusive.

11. The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any.

Remarks:

This Amendment is being filed to address an inadvertent clerical error in the original Form 4 relating to the allocation of the reported sales between Atlas Venture Fund X and AVOF. The aggregate number of shares sold by Atlas Venture Fund X and AVOF, as reported in the original Form 4, remains unchanged.

	/s/ Ommer Chohan, Attorney-in-Fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did Kymera Therapeutics (KYMR) report in this amended Form 4?

The amended Form 4 reports that Atlas funds associated with director Bruce Booth sold a total of 76,650 Kymera Therapeutics common shares on June 29, 2026, through 14 open-market transactions executed across a trading range near $105 to $112 per share.

Who actually sold the Kymera Therapeutics (KYMR) shares in this filing?

The shares were sold by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., not directly by Bruce Booth. Booth reports the trades as a member of their general partner entities and disclaims Section 16 beneficial ownership beyond any pecuniary interest he may have.

How many Kymera (KYMR) shares were sold and at what prices in this Form 4/A?

The filing shows 76,650 Kymera Therapeutics common shares sold in total, across 14 open-market trades. Weighted average prices in the footnotes indicate sale ranges from approximately $105.015 up to $111.63 per share, rather than a single execution price.

Was the Kymera Therapeutics (KYMR) insider sale made under a Rule 10b5-1 trading plan?

Yes. A footnote states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Atlas funds on December 11, 2025. Such plans pre-schedule trades, making the timing more mechanical and less reflective of short-term views on the stock.

Why is this Kymera Therapeutics (KYMR) Form 4 filing labeled as an amendment (Form 4/A)?

The filing corrects earlier misreported figures. A footnote explains that the originally reported number of shares disposed, and the ownership totals after the transactions, were inadvertently misstated. This amendment presents the corrected share counts for regulatory accuracy.

How is Bruce Booth’s ownership in Kymera (KYMR) characterized in this insider report?

The report describes the Kymera shares as held directly by Atlas venture funds. Footnotes note that Booth is a member of the funds’ general partner entities and disclaims Section 16 beneficial ownership of those securities, except to the extent of any pecuniary interest he may have.

Atlas funds trim Kymera (NASDAQ: KYMR) stake under 10b5-1 plan

Rhea-AI Filing Summary

Positive

Negative